Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury

Phase 4

Recruiting

• Conditions: Radiotherapy Side Effect; Radiotherapy; Complications; Cervical Cancer
• Interventions: Drug: KANG FU PEN

• Registration Number: NCT04819685
• Lead Sponsor: Peking Union Medical College Hospital

Brief Summary

A total of 520 cases will be randomly divided into Kang Fu Pen (liquid dressing) enema intervention group (experimental group) and non-enema intervention group (control group), according to the ratio of 1:1.

Detailed Description

All patients are planned to receive radical concurrent chemoradiotherapy. Intensity modulated radiotherapy (IMRT) will be used for external irradiation, with a dose of 45-50.4Gy /25-28 fractions. Combined three-dimensional intracavitary/interstitial (IC/IS) brachytherapy was applied. The preferred dose fraction plan is 6Gy\*5 fractions, or 7Gy\*4 fractions. Whether to adopt supplement radiotherapy can be decided by the tumor regression. Cisplatin 40 mg/m2 is recommended as the first choice for concurrent chemotherapy, and TP or TC can also be considered. Single-drug weekly therapy should be completed for at least 3 cycles, and combined 3-week regimen should be completed for at least 1 cycle.

Experimental group: from three days before radiotherapy to one week after radiotherapy, Kang Fu Pen (recombinant human superoxide dismutase) retention enema, 50ml/ time, once every other day. When rectal mucosa II degree reactions (NCI-CTCAE 5.0) occur, it is changed to 1 day/time until 1 week after mucosal remission.

Control group: 3 days before radiotherapy to the end of radiotherapy, no drug retention enema was used.

Study Timeline

• Status Verified: 2021-03
• Study Start: 2021-03-01
• Study First Submitted: 2021-03-17
• Study First Submitted QC: 2021-03-26
• Last Update Submitted: 2021-03-26
• Study First Posted: 2021-03-29
• Last Update Posted: 2021-03-29
• Primary Completion: 2023-03-01
• Study Completion: 2025-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 520

Inclusion Criteria

1. The patient is completely voluntary and has the ability to sign the research informed consent form within 30 days before enrollment;
2. Age ≥18 years old and ≤65 years old;
3. Pathologically confirmed cervical cancer;
4. Those with IB3, IIA2, IIB, IIIA, IIIB, and those with cervical tumor ≥ 4cm or involved parametrial in IIIC1 and IIIC2 (FIGO 2018 staging);
5. ECOG score 0-2 points;
6. The complete blood count and basal metabolic indexes in the 14 days before enrollment must meet the following requirements: NEUT≥1.5*10^9/L, HGB≥80g/L, PLT≥100*10^9/L, blood creatinine < 1.5mg/dl (133umol/L), AST and ALT are within 2 times of the upper limit of normal;
7. Those who have had regular bowel movements and had a negative stool routine test + occult blood before enrollment.

Exclusion Criteria

1. Those who have a history of allergy to superoxide dismutase use;
2. Patients with skin and mucous membrane infections, patients with obvious empyema or pelvic inflammatory disease;
3. Those who have had chronic colitis, ulcerative colitis, and non-specific proctitis in the past;
4. Those who have received cervical cancer surgery (including pelvic or retroperitoneal lymphadenectomy, excluding tumor biopsy), radiotherapy or chemotherapy;
5. Those who are expected to be unable to receive brachytherapy, or brachytherapy needs to use tumor elimination, uterine tube inserted alone in one fraction, or template plan;
6. Those who need to use fluorouracil or capecitabine or tigio in the concurrent chemotherapy regimen;
7. History of other malignant tumors;
8. Pregnant or lactating women;
9. Accompanied by active infection and fever;
10. Other serious diseases that may significantly affect the compliance of clinical trials, such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, and mental illness that require treatment.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
test group	KANG FU PEN	Intervention:Anti-radiation spray (liquid dressing)

Primary Outcome Measures

Name	Time	Method
Degree of rectal mucosal injury caused by acute radiation	Within 1 week after radiotherapy	the incidence of Vienna rectoscopy score ≥2 within 1 week after radiotherapy. Vienna rectoscopy score was used.

Secondary Outcome Measures

Name	Time	Method
Quality of life score	3 to 24 months after radiotherapy	EORTC QLQ-C30 (V3.0) was used to score quality of life before, during, and after radiotherapy.
overall survival (OS)	3 years after radiotherapy	Overall survival (OS) is defined as the time interval from randomization to death from any cause or, if no death, to the last follow-up.
Degree of rectal injury caused by chronic radiation	3 to 24 months after radiotherapy	incidence of RTOG score ≥2 at 3 to 24 months after radiotherapy. If the RTOG score ≥2 at 3 to 24 months after radiotherapy, rectoscopy will be used to evaluate the degree. If the RTOG score is 0 or 1, clinical classification is enough.
disease-progression-free survival (PFS)	3 years after radiotherapy	Progression-free survival (PFS) is defined as the time between randomization and the occurrence of local or regional recurrence, or distant metastasis, or death from any cause, based on the time of the first event and, if none of these events occurred, to the last follow-up.

Trial Locations

Locations (1)

Peking Union Medical College Hospital; 🇨🇳 Beijing, China